March 2026 Quarterly Activities Report & Appendix 4C
Filed with ASX · · 11 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Upsized $14M Placement Extends Runway Post IA
- Paradigm Achieves 50% Patient Dosing in Phase 3
- Appendix 4D and Half Year Report
- Drawdown of Tranche 3 under the Convertible Note Facility
- Published Canine Study Strengthens iPPS Phase 3 Rationale
Later from Paradigm Biopharmaceuticals
- DSMB 20% Review Supports Phase 3, Moldova Activated
- Results of Share Purchase Plan
- PAR Completes Enrolment in Pivotal Phase 3
- Drawdown of Tranche 4 under the Convertible Note Facility
- Paradigm Receives $5.75m R&D Tax Incentive Refund
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals